Immix Biopharma receives FDA RMAT designation for NCX-201 in r/r AL Amyloidosis
Immix Biopharma (IMMX) announced that the U.S. FDA has granted RMAT designation to sterically-optimized CAR-T NXC-201 for the treatment of ...